<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36238724</PMID><DateRevised><Year>2022</Year><Month>10</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Oct</Month><Day>05</Day></PubDate></JournalIssue><Title>medRxiv : the preprint server for health sciences</Title><ISOAbbreviation>medRxiv</ISOAbbreviation></Journal><ArticleTitle>Plasma cytokine levels reveal deficiencies in IL-8 and gamma interferon in Long-COVID.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2022.10.03.22280661</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1101/2022.10.03.22280661</ELocationID><Abstract><AbstractText>Up to half of individuals who contract SARS-CoV-2 develop symptoms of long-COVID approximately three months after initial infection. These symptoms are highly variable, and the mechanisms inducing them are yet to be understood. We compared plasma cytokine levels from individuals with long-COVID to healthy individuals and found that those with long-COVID had 100% reductions in circulating levels of interferon gamma (IFN&#x3b3;) and interleukin-8 (IL-8). Additionally, we found significant reductions in levels of IL-6, IL-2, IL-17, IL-13, and IL-4 in individuals with long-COVID. We propose immune exhaustion as the driver of long-COVID, with the complete absence of IFN&#x3b3; and IL-8 preventing the lungs and other organs from healing after acute infection, and reducing the ability to fight off subsequent infections, both contributing to the myriad of symptoms suffered by those with long-COVID.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Elizabeth S C P</ForeName><Initials>ESCP</Initials><Identifier Source="ORCID">0000-0001-6464-4372</Identifier></Author><Author ValidYN="Y"><LastName>Martins</LastName><ForeName>Thomas B</ForeName><Initials>TB</Initials></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>Harry R</ForeName><Initials>HR</Initials></Author><Author ValidYN="Y"><LastName>Coiras</LastName><ForeName>Mayte</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Kevin S</ForeName><Initials>KS</Initials></Author><Author ValidYN="Y"><LastName>Planelles</LastName><ForeName>Vicente</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Spivak</LastName><ForeName>Adam M</ForeName><Initials>AM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>medRxiv</MedlineTA><NlmUniqueID>101767986</NlmUniqueID></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>14</Day><Hour>3</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36238724</ArticleId><ArticleId IdType="pmc">PMC9558442</ArticleId><ArticleId IdType="doi">10.1101/2022.10.03.22280661</ArticleId><ArticleId IdType="pii">2022.10.03.22280661</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>